Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Pragmatic trial to define the magnitude and the predictive factors of the response to
omalizumab and mepolizumab in adult patients with severe refractory asthma and eligible to
both therapies.
AZ Delta AZ Delta Roeselare Brugmann University Hospital Centre Hospitalier Universitaire Dinant Godinne - UCL Namur Centre Hospitalier Universitaire Saint Pierre CHU de Charleroi Erasme University Hospital Grand Hôpital de Charleroi KU Leuven Universitair Ziekenhuis Brussel University Hospital of Liege University Hospital, Ghent University of Liege